Table 2 ALI factors and outcome divided between the ALI group with adverse outcome and the ALI group with no adverse outcome
Adverse Outcome | No Adverse Outcome | Total | P | |
|---|---|---|---|---|
Lower extremity ALI (verses upper extremity) n, % | 16, 84.2% | 8, 80.0% | 24, 82.8% | 0.78 |
Cause of ALI: Embolic n, % | 6, 31.6% | 1, 10.0% | 7, 24.1% | 0.20 |
Cause of ALI: Hypercoaguable State n, % | 5, 26.3% | 1, 10.0% | 6, 20.7% | 0.31 |
Cause of ALI: Iatrogenic n, % | 3, 15.8% | 5, 50.0% | 8, 27.6% | 0.05 |
Cause of ALI: PAD n, % | 5, 26.3% | 3, 30.0% | 8, 27.6% | 0.83 |
Threatened limb (Rutherford ALI 2a and 2b) | 13, 68.4% | 5, 50.0% | 18, 62.1% | 0.34 |
Atypical or confounded presentation, n, % | 9, 47.4% | 4, 40.0% | 13, 44.8% | 0.71 |
Pulses NOT documented | 9, 47.4% | 3, 30.0% | 12, 41.4% | 0.37 |
Patients with services other than vascular specialist consulted | 7, 36.8% | 1, 10.0% | 8, 27.6% | 0.13 |
Time to Heparin intravenous (initial treatment) Hours Mean (SD), range | 23.6 (39.4), 1.0–153.6 | 5.9 (6.8), 0.4–20.4 | 17.5 (33.8), 0.4–153.6 | 0.18 |
Time to Heparin intravenous (initial treatment) Hours Median | 10.1 | 2.4 | 8.6 | – |
Time to Definitive treatment Hours Mean (SD), range | 23.0 (39.7), 1.0–153.6 | 25.1(55.9), 0.4–184.6 | 23.8 (45.8), 0.4–184.6 | 0.91 |
Time to Definitive treatment Hours Median | 8.8 | 5.5 | 8.6 | – |
Heparin initiated ≥6 h from presentation | 16, 84.2% | 3, 30.0% | 19, 65.5% | < 0.01 |
NOT eligible for ALI Standard of Care n, % | 12, 63.2% | 0, 0.0% | 12, 41.4% | < 0.01 |
Death in follow up period n, % | 12, 63.2% | 1, 10.0% | 13, 44.8% | 0.01 |
Death in 3 months n, % | 12, 63.2% | 0, 0.0% | 12, 41.4% | < 0.01 |
Death within 1 month n, % | 9, 47.4% | N/A | 9, 31.0% | N/A |
ALI-related cause of death n, % | 6, 31.6% | N/A | 6, 46.1% | N/A |
Cancer-related cause of death n, % | 4, 21.1% | 1, 10.0% | 5, 38.4% | 0.46 |
Cardiac arrest from Myocardial Infarction as cause of death n, % | 2, 10.5% | 0, 0.0% | 2, 15.4% | 0.30 |
Amputation n, % | 2, 10.5% | N/A | 2, 6.8% | N/A |
Lifestyle-limiting claudication n, % | 5, 26.3% | N/A | 5, 17.2% | N/A |
Chronic limb-threatening ischemia, n, % | 3, 15.8% | N/A | 3, 10.3% | N/A |
Mean (SD) Follow up, months | 6 (14) | 24 (15) | 12 (17) | < 0.01 |
Median Follow up, months | 2 | 21 | 3 | – |